- ►cmlsupport.com [PDF] H Kantarjian, C Sawyers, A Hochhaus, F … - The New England journal of medicine, 2002 - nejm.highwire.org Results Imatinib induced major cytogenetic responses in 60 percent of the 454
patients with confirmed chronic-phase CML and complete hematologic responses in
95 percent. After a median follow-up of 18 months, CML had not progressed ... Cited by 1173 - Related articles - BL Direct - All 13 versions
- ►hematologylibrary.org M Talpaz, RT Silver, BJ Druker, JM Goldman, … - Blood, 2002 - bloodjournal.hematologylibrary.org Imatinib (Glivec [Gleevec in the United States; imatinib mesylate; Novartis
Pharma AG]) is a rationally designed, potent selective competitive inhibitor of
the Bcr-Abl protein-tyrosine kinase. 25-28 At therapeutic doses it also ... Cited by 807 - Related articles - BL Direct - All 5 versions
- ►hematologylibrary.org - Free from Publisher CL Sawyers, A Hochhaus, E Feldman, JM … - Blood, 2002 - bloodjournal.hematologylibrary.org Imatinib (imatinib mesylate; formerly STI571; Glivec in Europe; Gleevec in the
United States; Novartis Pharmaceuticals, Basel, Switzerland) is a rationally
designed, potent competitive inhibitor of the Bcr-Abl protein tyrosine ... Cited by 793 - Related articles - BL Direct - All 9 versions
JJ Molldrem, PP Lee, C Wang, K Felio, HM … - Nature Medicine, 2000 - nature.com Although the immune system has long been implicated in the control of cancer,
evidence for specific and efficacious immune responses in human cancer has been
lacking. In the case of chronic myelogenous leukemia (CML), either ... Cited by 446 - Related articles - BL Direct - All 2 versions
- ►uchicago.edu [PDF] H Kantarjian, F Giles, L Wunderle, K Bhalla, … - New England Journal of Medicine, 2006 - content.nejm.org Background Resistance to imatinib mesylate can occur in chronic myelogenous
leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107),
a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib ... Cited by 437 - Related articles - BL Direct - All 10 versions
- ►hematologylibrary.org - Free from Publisher H Kantarjian, M Talpaz, S O'Brien, G Garcia- … - Blood, 2004 - bloodjournal.hematologylibrary.org Imatinib mesylate (STI571, Gleevec; Novartis Pharmaceuticals, East Hanover, NJ)
is a selective Bcr-Abl protein tyrosine kinase inhibitor against c-abl, bcr/abl,
c-kit, and platelet-derived growth factor receptor (PDGF-R). 1,2 Imatinib ... Cited by 294 - Related articles - BL Direct - All 8 versions
- ►hematologylibrary.org - Free from Publisher HM Kantarjian, J Cortes, S O'Brien, FJ Giles, … - Blood, 2002 - bloodjournal.hematologylibrary.org Phase I and II studies of imatinib mesylate (STI571, Gleevec [Novartis
Pharmaceuticals, East Hanover, NJ]), a selective Bcr-Abl tyrosine kinase
inhibitor, 11 , 12 for CML in different phases have yielded extremely ... Cited by 217 - Related articles - BL Direct - All 5 versions
- ►bloodjournal.org Y Kano, M Akutsu, S Tsunoda, H Mano, Y … - Blood, 2001 - Am Soc Hematology The prognosis of CML and Ph + ALL is poor. 8 , 9 CML in the chronic phase can be
controlled by anticancer agents such as interferon- (IFN- ), hydroxyurea,
cytarabine, homoharringtonine, and busulfan, but survival is extremely ... Cited by 208 - Related articles - BL Direct - All 6 versions
- ►aacrjournals.org R Nimmanapalli, E O'Bryan, K Bhalla - Cancer research, 2001 - AACR HL-60/Bcr-Abl cells, with ectopic expression of p185 Bcr-Abl tyrosine kinase
(TK), and K562 cells, with endogenous expression of p210 Bcr-Abl TK, display a
high degree of resistance against antileukemic drug-induced apoptosis (G. ... Cited by 188 - Related articles - BL Direct - All 3 versions
- ►bloodjournal.org F Bonifazi, A de Vivo, G Rosti, F Guilhot, J … - Blood, 2001 - Am Soc Hematology Treatment of Philadelphia-positive (Ph + ) chronic myeloid leukemia (CML) with
interferon- (IFN- ) was introduced in the early 1980s, 1-3 was developed and
expanded at the MD Anderson Hospital, Houston, TX, 4 , 5 but did not become ... Cited by 187 - Related articles - BL Direct - All 6 versions
